IDEAYA Biosciences expands ESMO 2026 catalyst slate across eye and lung cancer
IDEAYA Biosciences will use ESMO 2026 to expand the clinical case for darovasertib across three uveal melanoma settings and test the durability of IDE849 responses in small-cell lung cancer.